CRMD CorMedix Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1410098 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY96.3%
TTM net income YoY-60.7%
TTM EPS YoY-71.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin77.0%
Operating margin38.3%
Net margin15.4%
FCF margin74.1%
EBITDA margin46.0%
Returns
ROE15.3%
ROA7.7%
ROIC (approx.)27.3%
Asset turnover0.50x
Leverage & solvency
Liabilities / assets49.7%
Debt / equity0.00x
Current ratio2.43x
Interest coverage—
Cash quality & payout
Operating cash flow / net income4.90x
Accruals ratio-29.8%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $311.71M | $43.47M | — | $65,408 | $190,936 |
| Cost of revenue | $22.09M | $3.03M | — | $3,734 | $148,938 |
| Gross profit | $275.75M | $40.28M | — | $61,674 | $41,998 |
| R&D expense | $19.33M | $3.94M | $13.16M | $10.68M | $13.13M |
| SG&A expense | $68.22M | $29.96M | $17.69M | $20.01M | $16.35M |
| Operating income | $150.14M | -$22.36M | -$48.96M | -$30.62M | -$29.44M |
| Interest expense | $2.78M | $36,000 | $34,296 | $26,515 | $15,943 |
| Pretax income | $150.02M | -$19.32M | -$46.34M | -$29.97M | -$29.46M |
| Income tax | -$13.04M | -$1.40M | — | -$585,617 | -$1.25M |
| Net income | $163.06M | -$17.93M | -$46.34M | -$29.70M | -$28.21M |
| EBITDA | $150.82M | -$22.20M | -$48.89M | -$30.54M | -$29.38M |
| EPS (basic) | 2.25 | -0.30 | -0.91 | -0.74 | -0.75 |
| EPS (diluted) | 2.04 | -0.30 | -0.91 | -0.74 | -0.75 |
| Weighted avg. shares (diluted) | 80,308 | 58,872 | 50.90M | 40.27M | 37.67M |
| Banking | |||||
| Net interest income | — | $1.40M | — | — | — |
| Balance sheet | |||||
| Cash & equivalents | $144.84M | $40.76M | $43.82M | $43.37M | $53.55M |
| Short-term investments | $3.69M | $11.04M | $32.39M | $15.64M | $12.15M |
| Receivables | $171.23M | $51.65M | — | — | — |
| Inventory | $29.72M | $7.60M | $2.11M | — | $3,008 |
| Current assets | $367.05M | $114.58M | $79.45M | $59.55M | $66.47M |
| PP&E, net | $5.96M | $1.83M | $1.87M | $1.61M | $1.47M |
| Goodwill | $30.00M | — | — | — | — |
| Intangibles | $379.07M | $1.84M | — | — | — |
| Total assets | $826.14M | $118.85M | $82.06M | $62.04M | $68.95M |
| Current liabilities | $174.27M | $33.84M | $11.40M | $6.31M | $5.35M |
| Long-term debt | $150,000 | — | — | — | — |
| Total debt | $150,000 | — | — | — | — |
| Total liabilities | $420.83M | $34.19M | $11.92M | $6.98M | $6.15M |
| Shareholders' equity | $405.31M | $84.66M | $70.14M | $55.06M | $62.80M |
| Net debt | -$144.69M | — | — | — | — |
| Shares outstanding | 79.26M | 64.41M | 54.94M | 42.82M | 38.09M |
| Cash flow statement | |||||
| Operating cash flow | $175.05M | -$50.62M | -$38.41M | -$24.36M | -$21.16M |
| Capital expenditure | $2.26M | $116,000 | $327,300 | $219,360 | $1.43M |
| Free cash flow | $172.79M | -$50.73M | -$38.74M | -$24.58M | -$22.58M |
| Investing cash flow | -$308.43M | $21.23M | -$17.06M | -$3.71M | -$9.13M |
| Financing cash flow | $238.45M | $26.32M | $55.92M | $17.90M | $41.76M |
| Depreciation & amortization | $677,000 | $154,000 | $70,755 | $84,618 | $61,890 |
| Stock-based compensation | $13.83M | $6.13M | $5.49M | $4.07M | $5.04M |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.